Evidence map›Paper›PMID 27058956›Full record

ArticlePLoS neglected tropical diseases2016

A Simple and Novel Strategy for the Production of a Pan-specific Antiserum against Elapid Snakes of Asia.

Kavi Ratanabanangkoon, Kae Yi Tan, Sukanya Eursakun, Choo Hock Tan, Pavinee Simsiriwong, Teeraporn Pamornsakda, Witthawat Wiriyarat, Chaiya Klinpayom, Nget Hong Tan

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
8.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 82 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Proteomics, toxicity and antivenom neutralization of Sri Lankan and Indian Russell's viper (The journal of venomous animals and toxins including tropical diseases · 2021
    Article
  18. Toxins · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Kavi RatanabanangkoonLaboratory of Immunology, Chulabhorn Research Institute, Bangkok, Thailand.
Kae Yi TanDepartment of Molecular Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Sukanya EursakunLaboratory of Immunology, Chulabhorn Research Institute, Bangkok, Thailand.
Choo Hock TanDepartment of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Pavinee SimsiriwongLaboratory of Immunology, Chulabhorn Research Institute, Bangkok, Thailand.
Teeraporn PamornsakdaDepartment of Pre-clinic and Applied Animal Science, Faculty of Veterinary Science, Mahidol University, Salaya, NakornPrathom, Thailand.
Witthawat WiriyaratDepartment of Pre-clinic and Applied Animal Science, Faculty of Veterinary Science, Mahidol University, Salaya, NakornPrathom, Thailand.
Chaiya KlinpayomThe Veterinary and Remount Department, The Royal Thai Army, NakornPrathom, Thailand.
Nget Hong TanDepartment of Molecular Medicine, University of Malaya, Kuala Lumpur, Malaysia.
University of Malaya · MYChulabhorn Research Institute · THMahidol University · THChulabhorn Graduate Institute · THRoyal Thai Army

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Snakebite envenomation is a serious medical problem in many tropical developing countries and was considered by WHO as a neglected tropical disease. Antivenom (AV), the rational and most effective treatment modality, is either unaffordable and/or unavailable in many affected countries. Moreover, each AV is specific to only one (monospecific) or a few (polyspecific) snake venoms. This demands that each country to prepare AV against its local snake venoms, which is often not feasible. Preparation of a 'pan-specific' AV against many snakes over a wide geographical area in some countries/regions has not been possible. If a 'pan-specific' AV effective against a variety of snakes from many countries could be prepared, it could be produced economically in large volume for use in many countries and save many lives. The aim of this study was to produce a pan-specific antiserum effective against major medically important elapids in Asia. The strategy was to use toxin fractions (TFs) of the venoms in place of crude venoms in order to reduce the number of antigens the horses were exposed to. This enabled inclusion of a greater variety of elapid venoms in the immunogen mix, thus exposing the horse immune system to a diverse repertoire of toxin epitopes, and gave rise to antiserum with wide paraspecificity against elapid venoms. Twelve venom samples from six medically important elapid snakes (4 Naja spp. and 2 Bungarus spp.) were collected from 12 regions/countries in Asia. Nine of these 12 venoms were ultra-filtered to remove high molecular weight, non-toxic and highly immunogenic proteins. The remaining 3 venoms were not ultra-filtered due to limited amounts available. The 9 toxin fractions (TFs) together with the 3 crude venoms were emulsified in complete Freund's adjuvant and used to immunize 3 horses using a low dose, low volume, multisite immunization protocol. The horse antisera were assayed by ELISA and by in vivo lethality neutralization in mice. The findings were: a) The 9 TFs were shown to contain all of the venom toxins but were devoid of high MW proteins. When these TFs, together with the 3 crude venoms, were used as the immunogen, satisfactory ELISA antibody titers against homologous/heterologous venoms were obtained. b) The horse antiserum immunologically reacted with and neutralized the lethal effects of both the homologous and the 16 heterologous Asian/African elapid venoms tested. Thus, the use of TFs in place of crude venoms and the inclusion of a variety of elapid venoms in the immunogen mix resulted in antiserum with wide paraspecificity against elapid venoms from distant geographic areas. The antivenom prepared from this antiserum would be expected to be pan-specific and effective in treating envenomations by most elapids in many Asian countries. Due to economies of scale, the antivenom could be produced inexpensively and save many lives. This simple strategy and procedure could be readily adapted for the production of pan-specific antisera against elapids of other continents.

Indexed as

AnimalsAntiveninsAsiaBungarusCross ReactionsElapidaeElapid VenomsEnzyme-Linked Immunosorbent AssayEpitopesFreund's AdjuvantHorsesImmune SeraImmunizationLethal Dose 50MiceSnake BitesAntiveninsElapid VenomsEpitopesFreund's AdjuvantImmune Sera

Identifiers

PMID27058956
PMCPMC4825939
OpenAlexW2314988735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.